



# Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients

Berna C. Özdemir<sup>1</sup> · Cristina Espinosa da Silva<sup>2,3</sup> · Dimitri Arangalage<sup>4</sup> · Pierre Monney<sup>5</sup> · Sabina A. Guler<sup>6</sup> · Uyen Huynh-Do<sup>7</sup> · Guido Stirnimann<sup>8</sup> · Lucia Possamai<sup>9</sup> · Roman Trepp<sup>10</sup> · Robert Hoepner<sup>11</sup> · Anke Salmen<sup>11</sup> · Camille L. Gerard<sup>12,13</sup> · Petr Hruz<sup>14</sup> · Lisa Christ<sup>15</sup> · Sacha I. Rothschild<sup>16,17</sup>

© The Author(s) 2023

**Correction to: Cancer Immunology, Immunotherapy**  
<https://doi.org/10.1007/s00262-023-03436-0>

The original version of this article unfortunately contained a mistake. In the Table 1, some of the endocrine tests every 3–6 months are misplaced under the column "every 4–6 weeks".

The correct Table 1 should be as indicated in the next page.

The original article can be found online at <https://doi.org/10.1007/s00262-023-03436-0>.

✉ Berna C. Özdemir  
Berna.oezdemir@insel.ch

<sup>1</sup> Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>2</sup> Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA

<sup>3</sup> Division of Epidemiology and Biostatistics, School of Public Health, San Diego State University, San Diego, USA

<sup>4</sup> Department of Cardiology, INSERM U1148, Bichat Hospital, University of Paris, Paris, France

<sup>5</sup> Department of Cardiology, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland

<sup>6</sup> Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>7</sup> Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>8</sup> Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

<sup>9</sup> Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK

<sup>10</sup> Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism (UDEM), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>11</sup> Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>12</sup> Department of Oncology, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland

<sup>13</sup> The Francis Crick Institute, London, UK

<sup>14</sup> Department of Gastroenterology, University Hospital Basel, Basel, Switzerland

<sup>15</sup> Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>16</sup> Department of Medical Oncology, University Hospital Basel, Basel, Switzerland

<sup>17</sup> Department Internal Medicine, Center for Oncology and Hematology, Cantonal Hospital Baden, Baden, Switzerland

**Table 1** Essential laboratory and functional tests to evaluate before and during treatment with immune checkpoint inhibitors (ICIs)

	Prior to ICI treatment	During ICI treatment			
	Baseline	During the first 3 months		After the first 3 months	
		Every ICI administration	Every 4–6 weeks	Every 4–6 weeks	Every 3–6 months
Liver	AST, ALT, GGT, ALP, total bilirubin	AST, ALT, GGT, ALP, total bilirubin	–	AST, ALT, GGT, ALP, total bilirubin	–
Endocrine function	Cortisol, TSH, fT3, fT4, AMH <sup>a</sup> , FSH, LH, Estradiol <sup>b</sup> , Glucose, Hb1Ac	TSH, fT4, fT3	–	–	TSH, fT4, fT3, AMH, FSH, LH, Estradiol, Hb1Ac
Heart	ECG, CK, Troponin T and I Echocardiography <sup>c</sup>	CK, Troponin T and I <sup>d</sup>	–	CK, Troponin T <sup>d</sup>	–
Kidney	Creatinine, Urea, Urine dipstick	Creatinine, Urea	–	Creatinine, Urea	Urine dipstick
Fluid and electrolyte balance	Sodium, Potassium	Sodium, Potassium	–	Sodium, Potassium	–
Bone metabolism	Calcium, Albumin, Vitamin D <sub>3</sub>	–	–	–	Calcium, Albumin
Bone marrow	Complete blood count	–	Complete blood count	Complete blood count	–
Latent infections	Hepatitis B and C, HIV, Tuberculosis	–	–	–	–
Coagulation and fibrinolysis	INR, PT, PTT, D-Dimer, Fibrinogen, Ferritin	–	–	–	INR, PT, PTT
Gastrointestinal function	FC, C.diff, CMV <sup>e</sup>	–	–	–	–
Lung function	Spirometry and DLCO <sup>f</sup>	–	–	–	–
Neurological function	Neurological examination (cranial nerves and motoric and sensory function)	–	–	–	–

ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CK creatine kinase, DLCO diffusing capacity for carbon monoxide, ECG electrocardiogram, FC fecal calprotectin, FSH follicle-stimulating hormone, GGT gamma-glutamyl transpeptidase, INR international normalized ratio, LDH lactate dehydrogenase, LH luteinizing hormone, PT prothrombin time, PTT partial thromboplastin time, TSH thyroid-stimulating hormone

<sup>a</sup>Female patients 18–42 years old

<sup>b</sup>Premenopausal female patients

<sup>c</sup>Patients at risk of developing ICI-related myocarditis (e.g., combination ICI, previous cardiotoxic therapies, cardiovascular diseases)

<sup>d</sup>During the first 4 doses before every ICI administration, thereafter every 3 doses

<sup>e</sup>Patients with preexisting diarrhea

<sup>f</sup>Patients with preexisting lung disease or radiotherapy to the lung or mediastinum

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.